Participants with schizophrenia retain the information necessary for informed consent during clinical trials.

ABSTRACT:

Objective

Cognitive impairment is a characteristic of schizophrenia. This impairment may affect the retention of information required for ongoing knowledgeable participation in clinical trials. This study monitored retention of study-related knowledge-including assessment of therapeutic misconception-in people with stable, DSM-IV schizophrenia during participation in placebo-controlled clinical trials of adjunctive agents. Stability was defined as being on an antipsychotic with no change in medication or dose over the previous 4 weeks.

Method

This longitudinal study assessed retention of clinical trial-related consent information. Individuals enrolling in 1 of 8 clinical trials were approached for participation. Participants came from research clinics and community mental he

SUBMITTER: Fischer BA 

PROVIDER: S-EPMC4482016 | biostudies-literature | 2013 Jun

REPOSITORIES: biostudies-literature